Gene Therapy: A Possible Alternative to CFTR Modulators?

Area of Science:

• Medical Genetics
• Pulmonology
• Pharmacology

Background:

• Cystic fibrosis (CF) is a genetic disorder primarily affecting the lungs, causing significant morbidity and mortality.
• The discovery of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene in 1989 paved the way for understanding CF.
• While life expectancy has increased due to supportive care and symptomatic treatments, a definitive cure for CF is still lacking.

Purpose of the Study:

• To evaluate the current landscape of CF treatment, focusing on CFTR modulator therapies and the persistent role of gene therapy.
• To discuss the potential long-term impact of emerging CFTR correctors and potentiators on patient quality of life and life expectancy.
• To explore the continued relevance and potential of gene therapy in the context of advancements in small molecule treatments for CF.

Main Methods:

• Review of current literature on CFTR modulator drugs (correctors and potentiators).
• Analysis of the limitations and accessibility of existing CFTR therapies.
• Discussion of the potential future role of gene therapy for cystic fibrosis.

Main Results:

• CFTR modulator drugs have improved lung function and quality of life for many CF patients.
• Current modulator therapies are not universally available or effective for all CFTR mutations.
• Long-term benefits of early and sustained use of modulator drugs on life expectancy are not yet fully established.

Conclusions:

• While CFTR modulators represent significant progress, they are not a cure and face accessibility challenges.
• Gene therapy, despite not yet being clinically realized, remains an attractive alternative and potential future curative strategy for CF.
• The development of new CFTR correctors and potentiators necessitates a re-evaluation of the ongoing role and potential of gene therapy in managing cystic fibrosis.